Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Executive VP Global Operations | March 05, 2024 | March 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date March 05, 2024 · Filed March 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 145,915 |
Last balance in matching sequence
After 2024-03-05 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-03-05 · Exercise / conversion · Acquired 22,576 · Balance 90,689 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Amount reflects the sale of 9,815 Ordinary Shares by the Reporting Person, as reported in a Form 4 filed on March 1, 2024, which was inadvertently omitted from the amount of securities beneficially owned by the Reporting Person following the transactions reported in a Form 4 filed on March 5, 2024. Row 2 · 2024-03-05 · Exercise / conversion · Acquired 55,226 · Balance 145,915 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Amount reflects the sale of 9,815 Ordinary Shares by the Reporting Person, as reported in a Form 4 filed on March 1, 2024, which was inadvertently omitted from the amount of securities beneficially owned by the Reporting Person following the transactions reported in a Form 4 filed on March 5, 2024. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 22,576 |
Reported balance
After 2024-03-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-05 · Exercise / conversion · Disposed 22,576 · Balance 22,576 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4: Restricted share units were granted on March 5, 2021, with 22,576 vested on March 5, 2022, March 5, 2023, March 5, 2024 and 22,576 vesting on March 5, 2025. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-05 · Exercise / conversion · Disposed 55,226 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5: Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Amount reflects the sale of 9,815 Ordinary Shares by the Reporting Person, as reported in a Form 4 filed on March 1, 2024, which was inadvertently omitted from the amount of securities beneficially owned by the Reporting Person following the transactions reported in a Form 4 filed on March 5, 2024.
F4: Restricted share units were granted on March 5, 2021, with 22,576 vested on March 5, 2022, March 5, 2023, March 5, 2024 and 22,576 vesting on March 5, 2025.
F5: Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2021 Filed Mar 8, 2021 16:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 90,304 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018512 · doc4.xml · derivative · entry 4 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,304 Underlying: Ordinary Shares · 90,304 shares Expires not disclosed F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 22,576 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and March 5, 2025. F7 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 22,576 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 16:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 11,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018512 · doc4.xml · derivative · entry 3 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,880 Underlying: Ordinary Shares · 11,940 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 11,940 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023. F6 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 11,940 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 16:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 6,183 | $10.58 | $65,443.35 |
DisclosureSEC source: 0001209191-21-018512 · doc4.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,048 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.700, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 16:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 11,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-018512 · doc4.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 16:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 9,795 | $10.85 | $106,284.57 |
DisclosureSEC source: 0001209191-21-015832 · doc4.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,291 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.775 to $11.005, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 16:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 19,514 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015832 · doc4.xml · derivative · entry 3 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,543 Underlying: Ordinary Shares · 19,514 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 19,514 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 19,515 vesting on February 28, 2024. F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 19,514 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 19,515 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 16:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 19,514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-015832 · doc4.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 16:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 2,079 | $11.13 | $23,135.32 |
DisclosureSEC source: 0001209191-21-011242 · doc4.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,572 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.1200 to $11.1300, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 16:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011242 · doc4.xml · derivative · entry 3 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,926 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 14, 2017, with 3,926 vesting on each of February 14, 2020 and February 14, 2021. F6 · derivative.expiration_date: Restricted share units were granted on February 14, 2017, with 3,926 vesting on each of February 14, 2020 and February 14, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 16:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,926 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-011242 · doc4.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 16:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 37,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009630 · doc4.xml · derivative · entry 6 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,884 Underlying: Ordinary Shares · 37,884 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F9 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on May 11, 2021. F9 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on May 11, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 16:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 6,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009630 · doc4.xml · derivative · entry 5 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,568 Underlying: Ordinary Shares · 6,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 6,567 vesting on each of February 9, 2020 and February 9, 2021 and 6,568 vesting on February 9, 2022. F8 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 6,567 vesting on each of February 9, 2020 and February 9, 2021 and 6,568 vesting on February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 16:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 14,527 | $12.72 | $184,796.51 |
DisclosureSEC source: 0001209191-21-009630 · doc4.xml · nonDerivative · entry 4 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,725 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 16:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 3,452 | $12.72 | $43,912.55 |
DisclosureSEC source: 0001209191-21-009630 · doc4.xml · nonDerivative · entry 3 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,252 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 16:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantOrdinary Shares | 27,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009630 · doc4.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,704 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units. F4 · price: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 16:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 6,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009630 · doc4.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 07:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 78,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014848 · doc4.xml · derivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,057 Underlying: Ordinary Shares · 78,057 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 19,514 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 19,515 vesting on February 28, 2024. F2 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 19,514 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 19,515 vesting on February 28, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 19:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 8,000 | $12.51 | $100,080.00 |
DisclosureSEC source: 0001209191-20-011287 · doc4.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,494 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 07:22 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009878 · doc4.xml · derivative · entry 6 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,926 Underlying: Ordinary Shares · 3,926 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on February 14, 2017, with 3,926 vesting on each of February 14, 2020 and February 14, 2021. F7 · derivative.expiration_date: Restricted share units were granted on February 14, 2017, with 3,926 vesting on each of February 14, 2020 and February 14, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 07:22 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 13,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009878 · doc4.xml · derivative · entry 5 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,090 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 11, 2020 pursuant to the satisfaction of performance criteria and vested on February 14, 2020. F6 · derivative.expiration_date: Restricted share units were granted on February 11, 2020 pursuant to the satisfaction of performance criteria and vested on February 14, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 07:22 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,878 | $12.14 | $22,790.84 |
DisclosureSEC source: 0001209191-20-009878 · doc4.xml · nonDerivative · entry 4 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,494 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.12 to $12.16, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 07:22 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 6,262 | $12.14 | $75,993.75 |
DisclosureSEC source: 0001209191-20-009878 · doc4.xml · nonDerivative · entry 3 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,372 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.12 to $12.16, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 07:22 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,926 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-009878 · doc4.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 07:22 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 13,090 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-009878 · doc4.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 07:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 13,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009048 · doc4.xml · derivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,090 Underlying: Ordinary Shares · 13,090 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 14, 2020. F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 14, 2020. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 06:56 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 3,144 | $12.24 | $38,487.90 |
DisclosureSEC source: 0001209191-20-008163 · doc4.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,618 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.2400 to $12.2450, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2020 Filed Feb 11, 2020 06:56 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 6,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008163 · doc4.xml · derivative · entry 3 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,135 Underlying: Ordinary Shares · 6,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 6,567 vesting on each of February 9, 2020 and February 9, 2021 and 6,568 vesting on February 9, 2022. F6 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 6,567 vesting on each of February 9, 2020 and February 9, 2021 and 6,568 vesting on February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2020 Filed Feb 11, 2020 06:56 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 6,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-008163 · doc4.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.